Purity ≥ 98%: HPLC and LC-MS Explained

Why 98% and Not 99% or 95%?

The 98% purity threshold for research-grade peptides is not an arbitrary marketing figure — it reflects a practical consensus among researchers, contract research organisations, and suppliers about the minimum standard at which a peptide can be considered fit for most research purposes. At purities below 98%, the proportion of impurities is substantial enough to meaningfully affect experimental results, biological activity measurements, and — critically, if the compound is being used in contexts involving humans — the safety and predictability of the dose.

Some applications require higher purity: peptides intended for in vivo work or clinical trial supply may require 99%+ purity with additional identity confirmation. Some applications may tolerate lower purity in specific analytical contexts. The 98% threshold represents the accepted floor for what the research community considers a credible general-purpose standard.

The figure is meaningful only when accompanied by the method used to determine it. Different analytical methods can produce different purity values for the same sample. A purity stated without a methodology — or determined by a method other than HPLC — is not directly comparable to the 98% standard derived from RP-HPLC analysis.

HPLC — High-Performance Liquid Chromatography

High-Performance Liquid Chromatography works by dissolving the sample in a liquid solvent (the mobile phase) and pumping it under high pressure through a column packed with a solid material (the stationary phase). Different components of the sample interact differently with the stationary phase — some move through the column quickly, others are retained longer. This differential movement, called chromatographic separation, produces a series of peaks as components exit the column at different times.

A UV detector at the column exit measures the absorbance of each peak. For peptides, the standard detection wavelength is 214 nm (where the peptide bond absorbs light) or 220 nm. The relative area of each peak, expressed as a proportion of total peak area, gives the purity percentage. A sample with a single large peak at 98.5% of total peak area, with the remaining 1.5% distributed across minor impurity peaks, would report as 98.5% pure by HPLC.

What HPLC Cannot Tell You

HPLC is an excellent purity measurement tool, but it has a fundamental limitation: it cannot confirm the identity of the major peak. If the largest peak in a chromatogram represents a completely different compound from the one stated on the label, HPLC will still report it as highly pure. This is not a theoretical concern — analyses of grey-market peptide samples have identified cases where the major component was an entirely different peptide or a non-peptide compound, despite high apparent purity by HPLC.

This is precisely why LC-MS identity confirmation is not optional. Purity without identity is an incomplete measurement.

LC-MS — Liquid Chromatography–Mass Spectrometry

Liquid Chromatography–Mass Spectrometry combines the separation capability of HPLC (the LC component) with the mass measurement capability of a mass spectrometer (the MS component). After chromatographic separation, the eluent from the column passes into an ionisation source, which converts the compound molecules into gas-phase ions. These ions are then separated in the mass analyser according to their mass-to-charge ratio (m/z) and detected.

The result is a mass spectrum — a plot of ion abundance against m/z — that gives the molecular weight of the compound with high precision. For a synthetic peptide, the observed molecular weight should match the theoretical molecular weight calculated from the amino acid sequence, within the analytical tolerance of the instrument (typically ± 0.5 Da for instruments using electrospray ionisation and single quadrupole detection, or substantially tighter for high-resolution instruments).

Interpreting the LC-MS Result

When reading an LC-MS result on a peptide COA, look for the following:

• Theoretical molecular weight: The calculated mass for the stated compound, derived from its amino acid sequence and the molecular formula. This should be stated on the COA alongside the CAS number.
• Observed (found) molecular weight: The mass measured by the instrument for the main peak in the LC-MS analysis.
• Delta or difference: Some COAs report the difference between theoretical and observed mass. A small delta (within instrument tolerance) confirms identity; a large delta is a concern.
• Multiple charge states: Larger peptides are often detected at multiple charge states (e.g., [M+2H]²⁺, [M+3H]³⁺). A credible COA from a well-equipped laboratory will show the relevant charge states and the calculated monoisotopic or average mass deconvoluted from these peaks.

Why Both Methods Are Required Together

The requirement for both HPLC and LC-MS on a credible peptide COA is not duplication — each method addresses a different dimension of quality. HPLC quantifies the proportion of the main component versus impurities. LC-MS confirms that the main component has the correct molecular mass for the claimed identity.

A COA showing only HPLC purity of 99.1% provides strong evidence of a highly pure sample, but no confirmation of what that sample is. A COA showing only LC-MS identity confirmation provides evidence of the correct molecular weight, but no quantification of how much of the sample that compound represents versus impurities.

Together, the two methods answer both questions: the sample is the stated compound (LC-MS), and it is at least 98% pure with only minor impurities present (HPLC). A COA that provides only one of these analyses is incomplete and should be treated as insufficient.

Common Analytical Deficiencies in Grey-Market COAs

Understanding the methods allows for more critical reading of documentation provided by grey-market suppliers. Common deficiencies include:

• Purity reported by UV absorbance at a single point, without column chromatography — this is not HPLC
• HPLC reported without stating the column type, mobile phase, or detection wavelength — the method cannot be assessed
• LC-MS data absent, or present but showing only a single mass peak with no charge-state analysis for larger peptides
• Mass reported only as nominal molecular weight without comparison to theoretical value
• COA produced using instrument software that is identifiable as consumer-grade or non-laboratory equipment

None of these deficiencies necessarily mean the product is poor quality — but they mean the documentation does not provide the standard of evidence that the 98% HPLC / LC-MS benchmark implies.

The Broader Verification Picture

HPLC purity and LC-MS identity are essential analytical checks, but they are not the complete picture. They do not address bacterial endotoxin content, residual solvents, sterility (for injectable compounds), or peptide folding and secondary structure in more complex cases. For research purposes, these additional tests may or may not be relevant depending on the application.

For individuals researching peptides in the UK context, the HPLC + LC-MS combination represents the practical minimum for documentary evidence of quality. Beyond the laboratory documentation, MHRA regulatory context and a consultation with a licensed healthcare professional are the two non-negotiable additional steps. This is not optional guidance — it is the only responsible framework for engaging with research compounds that exist outside the UK's licensed medicines framework.